Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.

Kurmasheva, Raushan T; Reynolds, C Patrick; Kang, Min H; Allievi, Cecilia; Houghton, Peter J; Smith, Malcolm A

Kurmasheva, Raushan T; Reynolds, C Patrick; Kang, Min H; Allievi, Cecilia; Houghton, Peter J; Smith, Malcolm A.

Affiliation

Kurmasheva RT; Nationwide Children's Hospital, Columbus, Ohio.

Pediatr Blood Cancer ; 61(5): 922-4, 2014 May.

Article in En | MEDLINE | ID: mdl-24166988

Subject(s)

DNA Topoisomerases, Type II/chemistry; Isoquinolines/pharmacology; Rhabdomyosarcoma/drug therapy; Sarcoma, Ewing/drug therapy; Topoisomerase II Inhibitors/pharmacology; Wilms Tumor/drug therapy; Animals; Bone Neoplasms/drug therapy; Bone Neoplasms/pathology; Cell Proliferation/drug effects; Drug Evaluation, Preclinical; Female; Humans; Isoquinolines/pharmacokinetics; Kidney Neoplasms/drug therapy; Kidney Neoplasms/pathology; Mice; Mice, SCID; Rhabdomyosarcoma/pathology; Sarcoma, Ewing/pathology; Tissue Distribution; Topoisomerase II Inhibitors/pharmacokinetics; Tumor Cells, Cultured; Wilms Tumor/pathology; Xenograft Model Antitumor Assays

Key words

developmental therapeutics; preclinical testing; topoisomerase 2 inhibitor

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Rhabdomyosarcoma / Sarcoma, Ewing / DNA Topoisomerases, Type II / Wilms Tumor / Topoisomerase II Inhibitors / Isoquinolines Language: En Journal: Pediatr Blood Cancer Year: 2014 Type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google